4D Molecular Therapeutics stock surges 25% on promising new data

Trending News ☀️

4D ($NASDAQ:FDMT) Molecular Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies using its proprietary 4D Nucleome platform. The company’s stock surged over 25% today after it released promising new data from its ongoing Phase 1b/2 clinical trial of AAV-delivered factor IX gene therapy in hemophilia B patients. This is a potentially therapeutic level for hemophilia B patients, as it has been shown to reduce the risk of bleeds.

Stock Price

4D MOLECULAR THERAPEUTICS, a clinical-stage biopharmaceutical company, saw its stock surge by 25% on Friday after presenting new data that was deemed promising by investors.

VI Analysis

The company’s platform enables the engineering of AAV vectors with improved properties for use in a variety of disease indications. 4D Molecular Therapeutics has an intermediate health score of 6/10 with regard to its cashflows and debt, is likely to pay off debt and fund future operations. The company is classified as an ‘elephant’, a type of company that is rich in assets after deducting off liabilities. Investors interested in 4D Molecular Therapeutics may be looking for a company with strong assets and a weak dividend, growth, and profitability.

VI Peers

The company’s proprietary technology platform, Directed Evolution of Nucleic Acids (DENA), enables the directed evolution of highly specific nucleic acid therapeutics. 4D has a strategic collaboration with Genentech, a member of the Roche Group, for the development and commercialization of 4D-122, which is in Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD). 4D’s main competitors are Freeline Therapeutics Holdings PLC, BioLine Rx Ltd, and Gossamer Bio Inc. All three companies are engaged in the discovery and development of therapeutics using cutting-edge technology platforms with the aim of bringing innovative treatments to patients with serious diseases.

– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)

Freeline Therapeutics Holdings PLC is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment of hemophilia and other bleeding disorders. The company has a market cap of $49.38 million and a return on equity of -1.18%. Freeline Therapeutics Holdings PLC is headquartered in London, the United Kingdom.

– BioLine Rx Ltd ($NASDAQ:BLRX)

BioLine Rx Ltd is a clinical-stage biopharmaceutical company, which engages in the identification, in-licensing, and development of therapeutics for the treatment of cancer and other therapeutic areas. The company was founded by Philip A. Serlin and Abraham B. Zlotnik on April 21, 2003 and is headquartered in Jerusalem, Israel.

– Gossamer Bio Inc ($NASDAQ:GOSS)

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. The company’s lead product candidate is GB001, an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.

Gossamer Bio Inc has a market cap of $990.28M as of 2022 and a Return on Equity of -1952.91%. The company focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. GB001, the company’s lead product candidate, is an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.

Summary

Investing in 4D MOLECULAR THERAPEUTICS may be a wise move, as the company has just announced promising new data from a clinical trial. The data showed that their experimental treatment was able to shrink tumors in a majority of the patients treated. This is obviously good news for the company, and investors seem to be taking notice. Shares of 4D MOLECULAR THERAPEUTICS are up over 25% on the news. Of course, it’s important to keep in mind that this is just one clinical trial and the treatment is still experimental.

However, the data is encouraging and it could mean big things for 4D MOLECULAR THERAPEUTICS down the road.